Multi-Institutional Series

A multi-institutional series is a research study that combines patient data from several hospitals or cancer centers to analyze outcomes, treatment responses, or disease patterns in a larger group than any single institution could provide alone. In asbestos-related disease research, these studies are especially important for rare cancers like mesothelioma, where no single hospital sees enough cases to draw firm conclusions. The pooled data strengthens statistical power and helps identify which treatments and patient factors most influence survival.

Origin

The term comes from clinical research methodology developed in the mid-20th century as oncology groups recognized that rare cancers required collaboration across centers. Cooperative groups like the International Mesothelioma Interest Group (IMIG) and the International Association for the Study of Lung Cancer (IASLC) have published influential multi-institutional series since the 1990s.

Significance in Asbestos Context

For someone diagnosed with mesothelioma or another asbestos-related cancer, multi-institutional series often provide the best available evidence about prognosis, surgical outcomes, and the value of treatments like extended pleurectomy/decortectomy, chemotherapy, or immunotherapy. These studies are frequently cited by expert witnesses to establish that a given exposure pattern causes disease, that latency periods are consistent with the patient's history, or that survival expectations support a particular damages calculation. Defendants sometimes attack these studies for combining patients across centers with different practices, while plaintiffs' experts rely on them precisely because they reflect a broader, more representative picture than a single hospital's experience. Patients should know that the survival statistics quoted to them often come from such series, and that their own outcome depends on individual factors the averages can't capture.

Example Sentence

The oncologist explained that the survival figures she quoted came from a multi-institutional series of over 1,000 pleural mesothelioma patients treated at major cancer centers across Europe and North America.

Related Terms

Epidemiology, Cohort Study, Case Series, Meta-Analysis, Prognosis, Latency Period

Notes

• Ask your treatment team which multi-institutional series their recommendations are based on, and whether your case profile matches the patients studied.
• When reading survival statistics, ask how recent the series is. Outcomes for mesothelioma have shifted with newer chemotherapy and immunotherapy regimens.
• Request copies of any published series your physicians reference; your legal team may need them to support causation and damages arguments.
• If you are offered enrollment in a clinical trial or registry, your data may contribute to future multi-institutional series. Keep records of consent forms and study identifiers.